Unprecedented Discovery and Development Engine

Back
Drug Discovery and Development Expertise

• Seasoned leadership team with decades of drug R&D and clinical experience at leading pharmaceutical companies
• Proven track record of delivering multiple clinical and marketed immunotherapies to patients

Back
Transformational Single-Cell Platform

• Pioneer in ultra-high throughput phenotyping and genotyping single-cell analysis
• Our Drug Intelligent Science (DIS™) approach leverages our proprietary single cell platform to rapidly identify differentiated therapeutic molecules and improve clinical probability of success

Back
Dynamic and Sustainable Pipeline

• We are developing a robust pipeline of novel therapeutic antibodies to modulate multiple immune cell types
• Majority of our programs are first-in-class with multiple preclinical candidates demonstrating proof of concept in animal models

Back
Unique Immune Profiling Translational Focus

• Engagement with the world’s leading clinical immunologists and oncologists to advance a clinical development strategy that better connects biological targets to patient characteristics
• We select indications based on unmet medical needs and our deep understanding of mechanisms of action

Back
Open-Innovation Strategy

• We continue to establish strategic partnerships with both leading pharmaceutical and biotechnology companies as well as academic institutions to accelerate the development of novel R&D technology platforms and therapeutics
• Our collaborations are architected for quality and speed while driven by our scientific strategy

• Seasoned leadership team with decades of drug R&D and clinical experience at leading pharmaceutical companies
• Proven track record of delivering multiple clinical and marketed immunotherapies to patients

• Pioneer in ultra-high throughput phenotyping and genotyping single-cell analysis
• Our Drug Intelligent Science (DIS™) approach leverages our proprietary single cell platform to rapidly identify differentiated therapeutic molecules and improve clinical probability of success

• We are developing a robust pipeline of novel therapeutic antibodies to modulate multiple immune cell types
• Majority of our programs are first-in-class with multiple preclinical candidates demonstrating proof of concept in animal models

• Engagement with the world’s leading clinical immunologists and oncologists to advance a clinical development strategy that better connects biological targets to patient characteristics
• We select indications based on unmet medical needs and our deep understanding of mechanisms of action

• We continue to establish strategic partnerships with both leading pharmaceutical and biotechnology companies as well as academic institutions to accelerate the development of novel R&D technology platforms and therapeutics
• Our collaborations are architected for quality and speed while driven by our scientific strategy

Our Multinational Presence

Join Our Team

Learn More

Americas

Europe

Asia